US Patent Issued to Seattle Children's Hospital on Oct. 7 for "Vivo gene therapy using intraosseous delivery of a lentiviralgene construct" (Washington Inventors)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,433,960, issued on Oct. 7, was assigned to Seattle Children's Hospital (Seattle).

"Vivo gene therapy using intraosseous delivery of a lentiviralgene construct" was invented by Carol Hsing Miao (Seattle), David J. Rawlings (Seattle) and Chong Li (Seattle).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods, compositions, and systems for treating subject(s) in need of plasma Factor VIII, particularly a subject having preexisting anti-FVIII inhibitory antibodies, are provided. The methods involve administering to the subject a therapeutically effective amount of an inflammation suppressor, a therapeutically effective amount of a CD8+ T cell depleting agen...